0.61
+0.0499(+8.91%)
Currency In USD
| Previous Close | 0.56 |
| Open | 0.57 |
| Day High | 0.63 |
| Day Low | 0.57 |
| 52-Week High | 7.75 |
| 52-Week Low | 0.47 |
| Volume | 114,233 |
| Average Volume | 1.49M |
| Market Cap | 2.05M |
| PE | -0.15 |
| EPS | -4.16 |
| Moving Average 50 Days | 0.86 |
| Moving Average 200 Days | 1.41 |
| Change | 0.05 |
If you invested $1000 in IMAC Holdings, Inc. (BACK) since IPO date, it would be worth $5.53 as of March 13, 2025 at a share price of $0.61. Whereas If you bought $1000 worth of IMAC Holdings, Inc. (BACK) shares 5 years ago, it would be worth $31.77 as of March 13, 2025 at a share price of $0.61.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ignite Proteomics to Present Data on MHC-II as a Predictor of Pembrolizumab Response at NCCN Annual Conference
GlobeNewswire Inc.
Feb 24, 2025 1:15 PM GMT
Golden, CO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (Nasdaq: BACK), today announced the presentation of new data demonstrating that MHC-II protein expression is a superior predictor of response t
Ignite Proteomics Completes Acquisition of PLA Code 0249U for Its Advanced Proteomic Breast Cancer Assay
GlobeNewswire Inc.
Feb 19, 2025 2:15 PM GMT
Golden, CO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (Nasdaq: BACK), today announced the completed transfer of Proprietary Laboratory Analyses (PLA) code 0249U – originally issued to Theralink Tec
Ignite Proteomics Announces Publication of Study Demonstrating Superiority of Protein Activation Analysis in Predicting Breast Cancer Therapy Response
GlobeNewswire Inc.
Feb 10, 2025 2:15 PM GMT
The new study adds to growing evidence that measuring activated proteins is key to cancer therapy selection. Golden, CO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (Nasdaq: BACK), announces the publ